A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression
Immune-checkpoint blockade (ICB) therapy has changed the clinical outcome of many types of aggressive tumors, but there still remain many cancer patients that do not respond to these treatments. There is an unmet need to develop a feasible clinical therapeutic platform to increase the rate of respon...
Saved in:
Main Authors: | Daniel Meraviglia-Crivelli (Author), Helena Villanueva (Author), Ashwathi Puravankara Menon (Author), Angelina Zheleva (Author), Beatriz Moreno (Author), María Villalba-Esparza (Author), Fernando Pastor (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma
by: Carla Lucia Esposito, et al.
Published: (2018) -
Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
by: Alexey Berezhnoy, et al.
Published: (2012) -
Assessing the activity of nonsense-mediated mRNA decay in lung cancer
by: Meng Wang, et al.
Published: (2017) -
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?
by: Mayte Sola, et al.
Published: (2020) -
CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer
by: Ashwathi Puravankara Menon, et al.
Published: (2024)